Therapeutic evaluation of Safoof-e-Pattharphori with Sharbat Bazoori Motadil in patients of renal stone

Abstract

Abstract Introduction: Stone formation is one of the common urological disorders; the Unani system of medicine provides an immense treasure of single and compound formulations for the safe management of urolithiasis. The objective of the study is to evaluate the effect of Unani medicine formulation Safoof-e-Pattharphori with Sharbat Bazoori Motadil in patients of Hasat-ul-Kulya (renal stone) as conservative treatment. Materials and Methods: This was a single-arm, open-labeled, pre and post without-control clinical trial entailing 30 diagnosed cases of Hasat-ul-Kulya (renal stone) up to 10 mm diagnosed by ultrasonography (USG), belonging to 18–65 years of age, either sex, and who had agreed to sign the informed consent form and follow up the protocol. The patients were exposed with Unani formulation, i.e., 5 g of Safoof-e-Pattharphori orally once daily with 50 ml of Sharbat Bazoori Motadil up to 45 days with three follow-ups. The assessments of subjective parameters were done at every 15th day of follow-up using an arbitrary scale. The assessments of objective parameters were carried out before and after the trial. The results were analyzed statistically using Wilcoxon signed-rank test, Student’s paired t-test (two-tailed), and proportion test. Results: The subjective parameters like pain in the abdomen showed significant relief with P < 0.001. Objective parameters such as USG abdomen showed significant results (P < 0.001). The size of the stone showed a statistically significant reduction (P < 0.001). No significant adverse changes were observed in safety parameters during and after the trial. Conclusion: It can be concluded that the Unani formulation Safoof-e-Pattharphori with Sharbat Bazoori Motadil is safe and effective in renal stone treatment.